Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
На конференции Американского общества клинической онкологии (ASCO) компания «Рош» представила новые данные по портфелю препаратов для лечения рака молочной железы
На конференции Американского общества клинической онкологии (ASCO) компания «Рош» представила новые данные по портфелю препаратов для лечения рака молочной железы
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
• Представлено 17 абстрактов с новыми данными по препаратам для лечения рака молочной железы (РМЖ).
• Достигнуто улучшение общей выживаемости (ОВ) при лечении препаратом атезолизумаб в комбинации с наб-паклитакселом при PD-L1-положительном метастатическом тройном негативном РМЖ (ТНРМЖ) во втором промежуточном анализе данных.
• Итоговые результаты исследования III фазы CLEOPATRA показали, что среди пациенток с метастатическим HER2-положительным РМЖ, получавших препарат пертузумаб, более 1/3 (37%) были живы спустя 8 лет.
• Достигнуто улучшение общей выживаемости (ОВ) при лечении препаратом атезолизумаб в комбинации с наб-паклитакселом при PD-L1-положительном метастатическом тройном негативном РМЖ (ТНРМЖ) во втором промежуточном анализе данных.
• Итоговые результаты исследования III фазы CLEOPATRA показали, что среди пациенток с метастатическим HER2-положительным РМЖ, получавших препарат пертузумаб, более 1/3 (37%) были живы спустя 8 лет.
Полный текст
Список литературы
1. Schmid P et al. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). ASCO, 2019.
2. Swain S et al. End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). ASCO, 2019.
3. Yao H et al. Oncotarget 2017; 8 (1): 1913–24.
4. Breastcancer.org. What is Triple-Negative Breast Cancer? https://www.breastcancer.org/symptoms/diagnosis/trip_neg?what.
5. Wolff AC et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.. J Clin Oncol 2013; 31 (31): 3997–4013.
6. Schmid P et al. N Engl J Med 2018; 379: 2108–21.
7. Adams S et al. Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nab-paclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC). ASCO, 2019.
8. Schneeweiss A et al. IMpassion130: expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). ASCO, 2019.
9. Binghe X et al. A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) v Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN). ASCO, 2019.
2. Swain S et al. End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). ASCO, 2019.
3. Yao H et al. Oncotarget 2017; 8 (1): 1913–24.
4. Breastcancer.org. What is Triple-Negative Breast Cancer? https://www.breastcancer.org/symptoms/diagnosis/trip_neg?what.
5. Wolff AC et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.. J Clin Oncol 2013; 31 (31): 3997–4013.
6. Schmid P et al. N Engl J Med 2018; 379: 2108–21.
7. Adams S et al. Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nab-paclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC). ASCO, 2019.
8. Schneeweiss A et al. IMpassion130: expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). ASCO, 2019.
9. Binghe X et al. A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) v Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN). ASCO, 2019.
2. Swain S et al. End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). ASCO, 2019.
3. Yao H et al. Oncotarget 2017; 8 (1): 1913–24.
4. Breastcancer.org. What is Triple-Negative Breast Cancer? https://www.breastcancer.org/symptoms/diagnosis/trip_neg?what.
5. Wolff AC et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.. J Clin Oncol 2013; 31 (31): 3997–4013.
6. Schmid P et al. N Engl J Med 2018; 379: 2108–21.
7. Adams S et al. Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nab-paclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC). ASCO, 2019.
8. Schneeweiss A et al. IMpassion130: expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). ASCO, 2019.
9. Binghe X et al. A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) v Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN). ASCO, 2019.
________________________________________________
2. Swain S et al. End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). ASCO, 2019.
3. Yao H et al. Oncotarget 2017; 8 (1): 1913–24.
4. Breastcancer.org. What is Triple-Negative Breast Cancer? https://www.breastcancer.org/symptoms/diagnosis/trip_neg?what.
5. Wolff AC et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.. J Clin Oncol 2013; 31 (31): 3997–4013.
6. Schmid P et al. N Engl J Med 2018; 379: 2108–21.
7. Adams S et al. Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nab-paclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC). ASCO, 2019.
8. Schneeweiss A et al. IMpassion130: expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). ASCO, 2019.
9. Binghe X et al. A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) v Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN). ASCO, 2019.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.